Form 8-K
8-K — Hemab Therapeutics Holdings, Inc.
Accession: 0001193125-26-233375
Filed: 2026-05-21
Period: 2026-05-21
CIK: 0002114044
SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — d102408d8k.htm (Primary)
EX-99.1 (d102408dex991.htm)
GRAPHIC (g102408g0521025606131.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d102408d8k.htm · Sequence: 1
8-K
false 0002114044 0002114044 2026-05-21 2026-05-21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2026
Hemab Therapeutics Holdings, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-43250
41-4241952
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
101 Main Street, Suite 1220
Cambridge, Massachusetts
02142
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (617) 553-3952
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
symbol(s)
Name of each exchange
on which registered
Common stock, $0.0001 par value per share
COAG
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and Financial Condition.
On May 21, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Description
99.1
Press Release issued by Hemab Therapeutics Holdings, Inc. on May 21, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEMAB THERAPEUTICS HOLDINGS, INC.
Date: May 21, 2026
By:
/s/ Benny Sørensen, M.D., Ph.D.
Name:
Benny Sørensen, M.D., Ph.D.
Title:
President and Chief Executive Officer
EX-99.1
EX-99.1
Filename: d102408dex991.htm · Sequence: 2
EX-99.1
Exhibit 99.1
Hemab Therapeutics Reports First Quarter 2026 Financial Results
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq
Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia
CAMBRIDGE, MA, USA & COPENHAGEN, Denmark – May 21 2026 – Hemab Therapeutics Holdings, Inc., a
clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced financial results for the first quarter ended March 31, 2026 and noted
recent business highlights.
“As a public company we continue our journey to accelerate progress and broaden impact for people living with serious
coagulation disorders with strong momentum across our clinical programs,” said Benny Sørensen, Chief Executive Officer of Hemab Therapeutics. “The Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia
recognizes both the potential for sutacimig to address a significant unmet need, and the urgency of bringing new treatment options to people living with Glanzmann thrombasthenia. With the successful completion of our IPO, our team remains focused on
advancing sutacimig toward pivotal trials, advancing HMB-002, while continuing to expand our pipeline with the goal of bringing new therapies to those living with high unmet need coagulation disorders.”
Corporate Highlights
In May 2026, the Company
completed an upsized IPO of 19,262,500 shares of its common stock, including the exercise in full of the underwriters’ option to purchase an additional 2,512,500 shares, at a public offering price of $18.00 per share. The offering raised gross
proceeds of $346.7 million before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company’s common stock is now trading on the Nasdaq Global Select Market under the ticker symbol
“COAG”.
Recent Business Highlights and Anticipated Milestones
Sutacimig: Sutacimig, a bispecific antibody, is the Company’s most advanced product candidate. The Company is advancing the clinical development
of sutacimig for two indications: Glanzmann thrombasthenia (GT) and Factor VII Deficiency.
Glanzmann Thrombasthenia:
GT is a serious inherited bleeding disorder with a prevalence of between 1 in 350,000 and 1 in 600,000 in the United States and caused by defects in platelet
aggregation. Current treatment options are limited to platelet transfusions, antifibrinolytics, recombinant Factor VIIa, and bone marrow transplantation.
•
The Company is conducting a Phase 1/2 clinical trial of sutacimig in patients with GT. Part B of the trial, which
evaluated the safety and tolerability profile of sutacimig and explored clinical efficacy over three months at multiple dose levels, is complete, and patients are continuing treatment with sutacimig in the long-term extension portion of the trial.
•
In March, sutacimig received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for
GT, a designation awarded to medicines that treat serious or life-threatening conditions where preliminary clinical evidence suggests the potential for a substantial improvement over the current standard of care.
•
The Company is preparing for a planned Phase 3 pivotal clinical trial in patients with GT that it anticipates
initiating in the second half of 2026.
•
Sutacimig has received Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA) for the
treatment of GT.
Factor VII Deficiency
Factor VII deficiency is a serious inherited coagulation disorder affecting approximately 1 in 500,000 people globally, that is characterized by impaired blood
clotting and increased bleeding risk.
•
The Company is conducting an ongoing Phase 2 clinical trial of sutacimig for Factor VII deficiency. The Company
expects to report data from the trial in late 2026 or early 2027.
HMB-002 - Von Willebrand
Disease
HMB-002 is a novel monovalent antibody designed for subcutaneous prophylactic treatment of Von
Willebrand Disease (VWD), one of the most common inherited bleeding disorders affecting approximately 140,000 patients.
•
The Company is evaluating HMB-002 in an ongoing Phase 1/2 clinical trial.
The Company expects to report data from the trial in late 2026 or early 2027.
Pipeline Expansion
The Company is also advancing multiple preclinical and discovery-stage assets focused on coagulation disorders with the goal of addressing critical gaps in the
treatment landscape.
First Quarter 2026 Financial Results
•
Cash Position and Cash Runway: Cash, cash equivalents, and marketable securities totaled $163.5 million
as of March 31, 2026, compared to $185.5 million as of December 31, 2025. The Company believes its current cash, cash equivalents, and marketable securities, together with net proceeds from the initial public offering completed in May
2026 of approximately $317.2 million, will enable it to fund its operating expenses and capital expenditure requirements into 2029.
•
Research and Development Expenses: Research and development expenses were $19.5 million for the three
months ended March 31, 2026, compared to $14.1 million for the three months ended March 31, 2025, reflecting advancement of clinical programs and regulatory activities.
•
General and Administrative Expenses: General and administrative expenses were $4.2 million for the
three months ended March 31, 2026, compared to $2.5 million for the three months ended March 31, 2025, including costs associated with preparing for and completing the initial public offering.
•
Net Loss: Net loss was $22.7 million, or $23.98 per share, for the three months ended March 31,
2026, compared to a net loss of $15.3 million, or $16.18 per share, for the three months ended March 31, 2025.
About Hemab Therapeutics
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to
sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of
innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment
of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.
Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains
forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations,
prospects and plans, objectives of management, the anticipated timelines for reporting data from Hemab’s clinical trials, the anticipated timelines for initiating a Phase 3 clinical trial of sutacimig, Hemab’s plans to expand its
pipeline, and the sufficiency of Hemab’s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,”
“predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification
and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and
Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; whether Hemab’s cash resources will be
sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the Securities and Exchange Commission
(SEC), including the Company’s most recent Form 10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press release represent
Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release.
Media:
Deerfield
Peg Rusconi
peg.rusconi@deerfieldgroup.com
Investors:
Hemab Therapeutics
Mads Behrndt
mads@hemab.com
Hemab Therapeutics
Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
(Unaudited)
Three Months Ended March 31,
2026
2025
Operating expenses
Research and development
$
19,461
$
14,101
General and administrative
4,151
2,459
Total operating expenses
23,612
16,560
Loss from operations
(23,612
)
(16,560
)
Other income (expense), net:
Interest income
1,219
473
Other (expense) income, net
(282
)
591
Total other income, net
937
1,064
Loss before income tax expense
(22,675
)
(15,496
)
Income tax (expense) benefit
(12
)
190
Net loss
$
(22,687
)
$
(15,306
)
Net loss per share, basic and diluted
$
(23.98
)
$
(16.18
)
Weighted average ordinary shares outstanding, basic and diluted
946,000
946,000
Other comprehensive (loss) income:
Net loss
(22,687
)
(15,306
)
Net unrealized gain (loss) on available-for-sale debt
securities
(614
)
974
Total comprehensive loss
$
(23,301
)
$
(14,332
)
Hemab Therapeutics Holdings, Inc.
Selected Consolidated Balance Sheets Data
(In thousands)
(Unaudited)
March 31,
December 31,
2026
2025
Assets
Cash and cash equivalents
$
49,860
$
87,974
Marketable securities
113,671
97,511
Prepaid expenses and other current assets
5,900
7,066
Property and equipment, net
648
609
Operating
right-of-use assets
939
1,092
Other non-current assets
4,240
531
Total assets
175,258
194,783
Liabilities and stockholders’ deficit
Accounts payable
5,682
5,734
Operating lease liabilities
544
647
Operating lease liabilities, net of current portion
519
573
Accrued expenses and other current liabilities
6,963
4,296
Total liabilities
13,708
11,250
Total convertible preferred stock and convertible preference shares
360,168
360,168
Total stockholders’ deficit
$
(198,618
)
$
(176,635
)
Hemab Therapeutics Holdings, Inc.
Selected Consolidated Statements of Cash Flows Data
(In thousands)
(Unaudited)
Three Months Ended March 31,
2026
2025
Net cash used in operating activities
(21,584
)
(13,033
)
Net cash used in investing activities
(15,847
)
(5,994
)
Net cash used in financing activities
(460
)
(29
)
Effect of foreign exchange rate changes on cash and cash equivalents
(223
)
—
Net decrease in cash and cash equivalents
$
(38,114
)
$
(19,056
)
GRAPHIC
GRAPHIC
Filename: g102408g0521025606131.jpg · Sequence: 6
Binary file (3689 bytes)
Download g102408g0521025606131.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Document and Entity Information
May 21, 2026
Cover [Abstract]
Amendment Flag
false
Entity Central Index Key
0002114044
Document Type
8-K
Document Period End Date
May 21, 2026
Entity Registrant Name
Hemab Therapeutics Holdings, Inc.
Entity Incorporation State Country Code
DE
Entity File Number
001-43250
Entity Tax Identification Number
41-4241952
Entity Address, Address Line One
101 Main Street
Entity Address, Address Line Two
Suite 1220
Entity Address, City or Town
Cambridge
Entity Address, State or Province
MA
Entity Address, Postal Zip Code
02142
City Area Code
(617)
Local Phone Number
553-3952
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Security 12b Title
Common stock, $0.0001 par value per share
Trading Symbol
COAG
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Entity Ex Transition Period
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration